126 related articles for article (PubMed ID: 21504761)
1. Thyromimetics: a journey from bench to bed-side.
Tancevski I; Rudling M; Eller P
Pharmacol Ther; 2011 Jul; 131(1):33-9. PubMed ID: 21504761
[TBL] [Abstract][Full Text] [Related]
2. Lipid lowering with thyroid hormone and thyromimetics.
Angelin B; Rudling M
Curr Opin Lipidol; 2010 Dec; 21(6):499-506. PubMed ID: 20935564
[TBL] [Abstract][Full Text] [Related]
3. Selective thyromimetics using receptor and tissue selectivity approaches: prospects for dyslipidemia.
Joharapurkar AA; Dhote VV; Jain MR
J Med Chem; 2012 Jun; 55(12):5649-75. PubMed ID: 22512468
[No Abstract] [Full Text] [Related]
4. Selective thyromimetics: tissue-selective thyroid hormone analogs.
Scanlan TS; Yoshihara HA; Nguyen NH; Chiellini G
Curr Opin Drug Discov Devel; 2001 Sep; 4(5):614-22. PubMed ID: 12825456
[TBL] [Abstract][Full Text] [Related]
5. Thyroid receptor ligands. 1. Agonist ligands selective for the thyroid receptor beta1.
Ye L; Li YL; Mellström K; Mellin C; Bladh LG; Koehler K; Garg N; Garcia Collazo AM; Litten C; Husman B; Persson K; Ljunggren J; Grover G; Sleph PG; George R; Malm J
J Med Chem; 2003 Apr; 46(9):1580-8. PubMed ID: 12699376
[TBL] [Abstract][Full Text] [Related]
6. Thyromimetics: a review of recent reports and patents (2004 - 2009).
Hirano T; Kagechika H
Expert Opin Ther Pat; 2010 Feb; 20(2):213-28. PubMed ID: 20100003
[TBL] [Abstract][Full Text] [Related]
7. Thyroid receptor ligands. Part 2: Thyromimetics with improved selectivity for the thyroid hormone receptor beta.
Hangeland JJ; Doweyko AM; Dejneka T; Friends TJ; Devasthale P; Mellström K; Sandberg J; Grynfarb M; Sack JS; Einspahr H; Färnegårdh M; Husman B; Ljunggren J; Koehler K; Sheppard C; Malm J; Ryono DE
Bioorg Med Chem Lett; 2004 Jul; 14(13):3549-53. PubMed ID: 15177471
[TBL] [Abstract][Full Text] [Related]
8. The thyroid hormone mimetic compound KB2115 lowers plasma LDL cholesterol and stimulates bile acid synthesis without cardiac effects in humans.
Berkenstam A; Kristensen J; Mellström K; Carlsson B; Malm J; Rehnmark S; Garg N; Andersson CM; Rudling M; Sjöberg F; Angelin B; Baxter JD
Proc Natl Acad Sci U S A; 2008 Jan; 105(2):663-7. PubMed ID: 18160532
[TBL] [Abstract][Full Text] [Related]
9. Thyroid hormone analogs for the treatment of dyslipidemia: past, present, and future.
Delitala AP; Delitala G; Sioni P; Fanciulli G
Curr Med Res Opin; 2017 Nov; 33(11):1985-1993. PubMed ID: 28498022
[TBL] [Abstract][Full Text] [Related]
10. Thyroid hormone analogues: where do we stand in 2013?
Meruvu S; Ayers SD; Winnier G; Webb P
Thyroid; 2013 Nov; 23(11):1333-44. PubMed ID: 23915136
[TBL] [Abstract][Full Text] [Related]
11. Thyroid Hormone Mimetics: the Past, Current Status and Future Challenges.
Elbers LP; Kastelein JJ; Sjouke B
Curr Atheroscler Rep; 2016 Mar; 18(3):14. PubMed ID: 26886134
[TBL] [Abstract][Full Text] [Related]
12. Discovery of novel indane derivatives as liver-selective thyroid hormone receptor β (TRβ) agonists for the treatment of dyslipidemia.
Shiohara H; Nakamura T; Kikuchi N; Ozawa T; Nagano R; Matsuzawa A; Ohnota H; Miyamoto T; Ichikawa K; Hashizume K
Bioorg Med Chem; 2012 Jun; 20(11):3622-34. PubMed ID: 22542282
[TBL] [Abstract][Full Text] [Related]
13. Selective activation of thyroid hormone signaling pathways by GC-1: a new approach to controlling cholesterol and body weight.
Baxter JD; Webb P; Grover G; Scanlan TS
Trends Endocrinol Metab; 2004; 15(4):154-7. PubMed ID: 15109613
[TBL] [Abstract][Full Text] [Related]
14. Potential Role of Thyroid Receptor β Agonists in the Treatment of Hyperlipidemia.
Jakobsson T; Vedin LL; Parini P
Drugs; 2017 Oct; 77(15):1613-1621. PubMed ID: 28865063
[TBL] [Abstract][Full Text] [Related]
15. Thyroid hormone analogs for treatment of hypercholesterolemia and heart failure: past, present and future prospects.
Morkin E; Ladenson P; Goldman S; Adamson C
J Mol Cell Cardiol; 2004 Dec; 37(6):1137-46. PubMed ID: 15572044
[TBL] [Abstract][Full Text] [Related]
16. Selective Thyroid Hormone Receptor-Beta (TRβ) Agonists: New Perspectives for the Treatment of Metabolic and Neurodegenerative Disorders.
Saponaro F; Sestito S; Runfola M; Rapposelli S; Chiellini G
Front Med (Lausanne); 2020; 7():331. PubMed ID: 32733906
[TBL] [Abstract][Full Text] [Related]
17. The resurgence of thyromimetics as lipid-modifying agents.
Tancevski I; Eller P; Patsch JR; Ritsch A
Curr Opin Investig Drugs; 2009 Sep; 10(9):912-8. PubMed ID: 19705333
[TBL] [Abstract][Full Text] [Related]
18. Thyroid receptor ligands. Part 4: 4'-amido bioisosteric ligands selective for the thyroid hormone receptor beta.
Li YL; Litten C; Koehler KF; Mellström K; Garg N; Garcia Collazo AM; Färnegård M; Grynfarb M; Husman B; Sandberg J; Malm J
Bioorg Med Chem Lett; 2006 Feb; 16(4):884-6. PubMed ID: 16303304
[TBL] [Abstract][Full Text] [Related]
19. Recent advances in thyroid research: selective thyroid hormone receptor modulators (STRMs).
Kraiem Z
Pediatr Endocrinol Rev; 2003 Dec; 1 Suppl 2():257-60; discussion 260. PubMed ID: 16444167
[TBL] [Abstract][Full Text] [Related]
20. Selective agonists and antagonists to thyroid hormone action.
Kraiem Z
Thyroid; 2005 Apr; 15(4):336-9. PubMed ID: 15876155
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
